There is a healthy appetite for continued investment in gene therapy, in new modalities and more indications, says an industry insider as he reflected on the prospects for the US gene therapy sector next year.
Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division.
